Overview of treatment of hepatitis B: Key approaches and clinical challenges

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 1, 2004, Pages 23-29

  Perrillo, Robert P ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Antiviral therapy; Hepatitis B; Interferon; Nucleoside analogues

Indexed keywords

ADEFOVIR; ALPHA2B INTERFERON; ENTECAVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; TELBIVUDINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 2942566183     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828675     Document Type: Conference Paper

References (35)

1. Perrillo RP. Hepatitis B: treatment strategies for currently available drugs. Curr Hep Reports 2003;2:63-70
2. Liaw YF, Leung N, Guan R, Lau GKK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003;18:239-245
3. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B. Hepatology 2001;34:1225-1241
4. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-540 (review)
5. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-540 (review)
6. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134
7. Chang T-T, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002;36:300A (Abst)
8. van Bommel F, Wunsche T, Schurmann D, et al. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection. Hepatology 2003;38:275A (Abst)
9. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-916
10. Nair S, Perrillo RP. Hepatitis B and D. In: Zakim D, Boyer T, eds. Hepatology: A Textbook of Liver Disease. Philadelphia: Saunders; 2003:959-1016
11. Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-1022
12. Honkoop P, de Man RA, Niesters HG, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639
13. Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004;24(suppl 1): 31-36
14. Locarnini SA. Molecular virology of hepatitis B. Semin Liver Dis 2004;24(suppl 1):3-10
15. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117
16. Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-113
17. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis virus. Gastroenterology 2004;126:81-90
18. Peters MG, Hann HW, Heathcote E, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant hepatitis B. Gastroenterology 2004;126:91-101
19. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297
20. Colonno RJ, Weinheimer S, Rose R, et al. Emerging amino acid substitutions in lamivudine-resistant HBV that result in reduced susceptibility to entecavir. Presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL
21. Lai C-L, Leung NWY, Teo E-T, et al. Results of a one-year international phase IIB comparative trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B. Hepatology 2003;38:262A (Abst)
22. Sung JJY, Lai JY, Zeuzem S, et al. A randomized double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naïve patients with chronic hepatitis B: week 52 analysis. J Hepatol 2003;38:25-26 (Abst)
23. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323
24. Nair S, Perrillo R. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34:1021-1026
25. Cooksley WGE, Piratvisuth T, Lee S-D, et al. Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305
26. Cooksley WG. Treatment with interferons in patients with hepatitis B. Semin Liver Dis 2004;24(suppl 1):45-54
27. Marcellin P, Lau GKK, Bonino F, et al. A phase II, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2° (40KD) (Pegasys®) alone or in combination with lamivudine vs lamivudine in 537 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B. Hepatology 2003;38:724A (Abst)
28. Hansen HLA, Senturk H, Zeuzem S, et al. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg positive chronic hepatitis B: a randomized controlled trial in 307 patients. Presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases; October 28, 2003; Boston, MA
29. Westland C, Delaney W IV, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-116
30. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002
31. Chu C-J, Keeffe EB, Han S-H, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003;125:444-451
32. Korba BE, Cote P, Hornbuckle W, et al. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferono against WHV replication in chronic carrier woodchucks. Antivir Ther 2000;5:95-104
33. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000;46:562-568
34. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/ interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804
35. Samuel D. Management of Hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24(suppl 1):55-62